PDF(Sci-hub)
Abstract：
BACKGROUND: Venous leg ulcers (VLUs) are common throughout the world, which seriously affects the patient\'s work and life. Relevant researches suggested that sclerosing foam (SF) has potential benefits for VLUs. However, there is no consistent conclusion. The purpose of our study is to assess whether SF is effective and safe for VLUs.
METHODS: Relevant clinical randomized controlled trials will be obtained from a search of 8 databases (with no language restrictions) from their inception to May 2020: PubMed, the Cochrane Library, EMBASE, Web of Science, China National Knowledge Infrastructure Database, Wanfang Database, China Science and Technology Journal Database, and Chinese Biological Medicine. Data will be analyzed using RevMan 5.3 after literature screening and data extraction according to predefined inclusion and exclusion criteria. Cochrane Collaboration Risk of bias Tool will be applied in evaluating the quality of enrolled articles. The primary outcome is Closure of venous leg ulcers, ulcer healing rate, adverse events related to SF. The secondary outcomes include ulcer healing time, ulcer recurrence rate, pain. Risk ratio will be used for categorical data; mean differences will be used for measurement data. Where possible and appropriate, meta-analysis will be performed for each outcome.
RESULTS: To clarify whether Sclerosing foam can be safe and efficient on treating venous leg ulcers.
CONCLUSIONS: Our review will provide useful information to judge whether Sclerosing Foam is an effective and safe intervention for patients with venous leg ulcers.
METHODS: Relevant clinical randomized controlled trials will be obtained from a search of 8 databases (with no language restrictions) from their inception to May 2020: PubMed, the Cochrane Library, EMBASE, Web of Science, China National Knowledge Infrastructure Database, Wanfang Database, China Science and Technology Journal Database, and Chinese Biological Medicine. Data will be analyzed using RevMan 5.3 after literature screening and data extraction according to predefined inclusion and exclusion criteria. Cochrane Collaboration Risk of bias Tool will be applied in evaluating the quality of enrolled articles. The primary outcome is Closure of venous leg ulcers, ulcer healing rate, adverse events related to SF. The secondary outcomes include ulcer healing time, ulcer recurrence rate, pain. Risk ratio will be used for categorical data; mean differences will be used for measurement data. Where possible and appropriate, meta-analysis will be performed for each outcome.
RESULTS: To clarify whether Sclerosing foam can be safe and efficient on treating venous leg ulcers.
CONCLUSIONS: Our review will provide useful information to judge whether Sclerosing Foam is an effective and safe intervention for patients with venous leg ulcers.
摘要：
背景：腿部静脉溃疡（VLU）在全世界都很常见，严重影响患者的工作和生活。相关研究表明，硬化泡沫（SF）对VLU具有潜在的益处。然而,没有一致的结论。我们研究的目的是评估SF对VLU是否有效和安全。
方法：从开始到2020年5月，将从8个数据库（无语言限制）的搜索中获得相关的临床随机对照试验：PubMed，Cochrane图书馆,EMBASE,WebofScience,中国国家知识基础设施数据库,万方数据库,中国科技期刊数据库,和中国生物医药。根据预定义的纳入和排除标准，在文献筛选和数据提取后，使用RevMan5.3分析数据。Cochrane协作偏差风险工具将用于评估注册文章的质量。主要结果是静脉性腿部溃疡的闭合，溃疡愈合率，与SF相关的不良事件。次要结果包括溃疡愈合时间，溃疡复发率,疼痛。风险比率将用于分类数据；平均差异将用于测量数据。在可能和适当的情况下，将对每个结果进行荟萃分析。
结果：为了阐明硬化泡沫在治疗下肢静脉性溃疡方面是否安全有效。
结论：我们的综述将提供有用的信息来判断硬化泡沫对下肢静脉性溃疡患者是否是一种有效和安全的干预措施。
方法：从开始到2020年5月，将从8个数据库（无语言限制）的搜索中获得相关的临床随机对照试验：PubMed，Cochrane图书馆,EMBASE,WebofScience,中国国家知识基础设施数据库,万方数据库,中国科技期刊数据库,和中国生物医药。根据预定义的纳入和排除标准，在文献筛选和数据提取后，使用RevMan5.3分析数据。Cochrane协作偏差风险工具将用于评估注册文章的质量。主要结果是静脉性腿部溃疡的闭合，溃疡愈合率，与SF相关的不良事件。次要结果包括溃疡愈合时间，溃疡复发率,疼痛。风险比率将用于分类数据；平均差异将用于测量数据。在可能和适当的情况下，将对每个结果进行荟萃分析。
结果：为了阐明硬化泡沫在治疗下肢静脉性溃疡方面是否安全有效。
结论：我们的综述将提供有用的信息来判断硬化泡沫对下肢静脉性溃疡患者是否是一种有效和安全的干预措施。
